BioCentury Podcasts 팟캐스트 프로그램

채널 • 2개의 프로그램

생명 과학

생명 과학

매주 업데이트
생명 과학

생명 과학

격주 업데이트

3일 전

Ep. 265 - RFK Jr. & HHS, Blenrep's Comeback, China Deals

Giving RFK Jr. control of HHS would be disastrous, argues Washington Editor Steve Usdin on the latest BioCentury This Week podcast. Expanding on his Editor’s Commentary, Usdin explains why Kennedy would be an unmitigated disaster for FDA, NIH and CMS, for biopharmas and for patients. He calls on biopharma leaders to speak out and affirm basic truths, even if it puts them in harm’s way.BioCentury’s editors also discuss why new data for GSK's Blenrep — an oncology therapy withdrawn two years ag...

3일 전

•

30분
11월 5일

Ep. 263 - Alzheimer Insights: Anti-Amyloid Safety & Tau Teaser

It’s too soon to conclude anti-amyloid therapies are safe for use by Alzheimer’s patients in the real world, even as early reports are encouraging, argues BioCentury Executive Editor Selina Koch on the latest BioCentury This Week podcast. Koch and colleagues discuss takeaways from this year’s Clinical Trials on Alzheimer’s Disease annual meeting, including conclusions from adverse event data for Leqembi lecanemab and what the true test of appropriate use and safety for the drug might look lik...

11월 5일

•

35분
10월 31일

Ep. 71 - Pazdur Unplugged: FDA Director Richard Pazdur on the Past, Future of Cancer Treatments

Richard Pazdur, director of FDA’s Oncology Center of Excellence, joined FDA in 1999. Looking back on his 25th anniversary, he draws a line between unpopular decisions at the start of his tenure and a surge in cancer drug development over the last 20 years. He believes this and other lessons from the regulation of oncology can be applied broadly across FDA. The BioCentury Show discussed these lessons, as well as Pazdur’s views about advisory committees, pragmatic trials, dose optimization and ...

10월 31일

•

42분
10월 8일

Ep. 258 - Breaking the Bear: 4Q Public Markets Preview

Biopharma buysiders and bankers at long last believe the conditions are ripe for biotech growth and outperformance, BioCentury’s Stephen Hansen says on the latest BioCentury This Week podcast. Hansen and colleagues take stock of the sector’s growth potential after three long years of the bear market as they discuss BioCentury’s 4Q24 Public Markets Preview.Also on this week’s show, Washington Editor Steve Usdin discusses his Editor’s Commentary, in which he argues that FDA leaders planned refo...

10월 8일

•

40분
10월 1일

Ep. 257 - Schizophrenia, Sickle Cell Drugs, D.C. Update

Approval of BMS’s first-in-class schizophrenia drug is good news for patients and the company’s thinning pipeline alike, but maximizing Cobenfy’s commercial potential depends on readouts in additional indications. On the latest BioCentury This Week podcast, BioCentury’s editors assess the significance of the new therapy and what the pharma needs to do to make its launch a success.They also discuss the impact of the withdrawal of Pfizer's sickle cell therapy; the work left unfinished on biotec...

10월 1일

•

32분
9월 17일

Ep. 253 - IPOs, GLP-1 & Obesity, AI & Biotech

On the latest BioCentury This Week podcast, BioCentury’s editors assess the shifting market for biotech IPOs, including the profiles of the three companies that went public on NASDAQ last week, the aftermarket performance of the year's IPO class, and the prospects for more companies to make their own debut in the coming months. BioCentury’s editors also discuss whether the rush to GLP-1s for obesity will mirror the development of PD-1s for cancer and the impact on biopharma of the recent main...

9월 17일

•

33분
9월 20일

Ep. 254 - Takeaways from Grand Rounds 2024

On a special edition of the BioCentury This Week podcast, BioCentury’s editors deliver their takeaways from the debut Grand Rounds conference, which focused on whether biotech can write a more successful playbook for translating from target to product. Weaving together takeaways from the panels, fireside chat and keynote at the conference, the editors assess the tensions between generalizability and fit-for-purpose models, between having control and capturing complexity, and, in human data, b...

9월 20일

•

35분
8월 27일

Ep. 249 - Biotech IPO Buzz, Pharma Deal Trends, Washington Update

Shaking up an underwhelming year for fresh biotech paper, a trio of biotechs filed to go public on NASDAQ last week. On the latest BioCentury This Week podcast, BioCentury’s editors discuss the IPO filings by MBX and Massachusetts companies Zenas and Bicara. Washington Editor Steve Usdin returns to the podcast to provide updates on the Inflation Reduction and Biosecure acts, as well as the life sciences policies of presidential candidates Donald Trump and Kamala Harris. And Director of Biopha...

8월 27일

•

29분
9월 4일

Ep. 250 - Biosecure, Priority Review Vouchers & Target Discovery

A vote on the Biosecure Act in the U.S. House of Representatives early next week shines the spotlight back on legislation seeking to rein in Chinese CDMOs and genomics companies, as Congress returns to work. On the latest BioCentury This Week podcast, BioCentury’s editors handicap the legislation’s chances of passage in the House and Senate and assess what’s at stake for the law authorizing rare pediatric disease priority review vouchers.They also discuss the results of BioCentury’s snap poll...

9월 4일

•

30분
9월 10일

Ep. 252 - Akeso's Bispecific, Vaxcyte & Woodcock's Quality Mindset

Will bispecifics be the drugs to dethrone cancer’s biggest blockbusters? Akeso is the latest company with a bispecific to impress in a head-to-head study, this one for non-small cell lung cancer. On the latest BioCentury This Week podcast, BioCentury’s editors discuss the latest data from Akeso’s ivonescimab, a VEGFxPD-1 bispecific antibody that went up against Keytruda pembrolizumab in one of its largest indications, first-line non-small cell lung cancer.The editors also discuss data from&nb...

9월 10일

•

19분

BioCentury Podcasts leverage three decades of biopharma intelligence with thoughtful, accurate, and objective insights. BioCentury editors spotlight key scientific opinion leaders, corporate decision-makers, venture capitalists, and patient advocates, keeping you informed on the most current biotech stories and highlighting life science innovations.

웹사이트

인기 프로그램

Ep. 265 - RFK Jr. & HHS, Blenrep's Comeback, China Deals

Ep. 263 - Alzheimer Insights: Anti-Amyloid Safety & Tau Teaser

Ep. 71 - Pazdur Unplugged: FDA Director Richard Pazdur on the Past, Future of Cancer Treatments

Ep. 258 - Breaking the Bear: 4Q Public Markets Preview

Ep. 257 - Schizophrenia, Sickle Cell Drugs, D.C. Update

Ep. 253 - IPOs, GLP-1 & Obesity, AI & Biotech

Ep. 254 - Takeaways from Grand Rounds 2024

Ep. 249 - Biotech IPO Buzz, Pharma Deal Trends, Washington Update

Ep. 250 - Biosecure, Priority Review Vouchers & Target Discovery

Ep. 252 - Akeso's Bispecific, Vaxcyte & Woodcock's Quality Mindset

소개